RGEN · Repligen Corp
Price
Snapshot
50 fields · last close| Market Cap | $11.35B |
| P/E | 276.85 |
| Float | 60.28M |
| Beta | 1.13 |
| Volatility 30D | 52.6% |
| Exchange | NASDAQ |
| Sector | Life Sciences Tools & Services |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 68.3 |
| Price | 177.30 |
| Change | +0.21% |
| Prev Close | 176.93 |
| Open | 179.45 |
| Day Low | 175.96 |
| Day High | 185.03 |
| Avg Vol | 1 |
| Avg $ Vol | $192.1M |
| 52W High | 198.87 |
| 52W Low | 100.99 |
| 52W Pos | 78.0% |
| From High | −10.85% |
| From Low | +75.56% |
| Max DD 1Y | −40.28% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −1.46% |
| SMA 50 | +0.22% |
| SMA 200 | +22.83% |
| RSI (14) | 51.1 |
| Vol 90D | 50.3% |
| Vol 1Y | 46.1% |
| 1Y Range | 101–199 |
| Daily bars | 540 |
| Perf Week | −2.96% |
| Perf Month | −3.15% |
| Perf Quarter | +35.43% |
| Perf Half Y | +56.68% |
| Perf Year | +14.01% |
| Perf YTD | +7.88% |
| Prev Day | +0.21% |
| Clavix | B- |
| Debt / Eq | 0.26 |
| Curr Ratio | 8.37 |
| Int Cover | -3.8× |
| FCF Margin | 8.5% |
| Rev Growth | +16.4% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 14 / 19 |
Clavix risk grade
regraded every trading dayRGEN grades B-, 68.3 of 100. Steadiest on News Sentiment (69), most exposed on Price Stability (49, fragile). 1 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 14 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| RGEN | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.13 | 1.18 |
| 30-day realized volatilityannualized, from daily closes | 52.6% | 32.3% |
| Max drawdown, past yearworst peak-to-trough fall | −40.3% | — |
| Typical daily movemedian absolute daily change | 1.65% | — |
| Days beyond ±3%of the last 252 sessions | 65 (26%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| RGEN | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.13 | 1.18 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 47% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| RGEN | |
|---|---|
| 1 week | −3.0% |
| 1 month | −3.2% |
| Year to date | +7.9% |
| 1 year | +14.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| RGEN | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 23 Jul |
| Average score0 most bearish, 100 most bullish | 70 |
| Bullish · bearisharticles above 60 · below 40 | 27 · 3 |
| Directionarticles whose tone is improving vs worsening | 27 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| RGEN | |
|---|---|
| Revenue growthyear over year | +16.4% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openRepligen posted 13% organic growth, meaning growth excluding acquisitions, even as its Filtration segment lagged. Proteins and Process Analytics are driving momentum, Filtration is expected to recover to mid-single-digit growth in 2026, and the BioLife acquisition will add cell therapy consumables that are expected to boost earnings per share once the deal closes.
Repligen (RGEN) has completed an acquisition of BioLife Solutions, and the two companies' combined capabilities will now support customers across the bioproduction workflow. The article provides no further details such as deal value, close date, or integration plan.
Repligen announced on October 6, 2026 that it has completed its previously announced acquisition of BioLife Solutions, a supplier of cell processing tools and services for the cell and gene therapy market.
Repligen has completed its acquisition of BioLife Solutions, a supplier of cell processing tools and services for cell and gene therapy. BioLife shareholders received $11.25 per share in cash plus 0.1442 shares of Repligen stock for each BioLife share they held.
Repligen (RGEN) announced it has completed its acquisition of BioLife Solutions (BLFS), a supplier of cell processing tools and services for cell and gene therapy, on October 6, 2026. BioLife's biopreservation media products, including CryoStor, support 18 commercially approved therapies. The article is truncated and does not disclose the deal consideration.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| TECH | Bio-Techne Corp | B | $11.39B | 62.64 | 1.29 | Compare |
| TEM | Tempus AI Inc | D- | $11.51B | — | 2.54 | Compare |
| AVTR | Avantor Inc | B- | $11.60B | — | 0.98 | Compare |
| QGEN | Qiagen NV | B+ | $10.35B | 25.34 | 0.60 | Compare |
| TXG | 10X Genomics Inc | C- | $9.09B | — | 2.00 | Compare |
| BRKR | Bruker Corp | C | $8.73B | — | 1.24 | Compare |
| CRL | Charles River Laboratories International Inc | B- | $16.21B | — | 1.38 | Compare |
| RVTY | Revvity Inc | B | $17.56B | 74.00 | 1.09 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.